Method of treating graft versus host disease using IL-2 muteins

Patent metadata

Field	Value
Publication number	US-9732134-B2
Application number	US-201213672417-A
Country	US
Kind code	B2
Filing date	Nov 8, 2012
Priority date	Jan 21, 2009
Publication date	Aug 15, 2017
Grant date	Aug 15, 2017

Abstract

Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.

First claim

What is claimed is:

1. A method of treating graft versus host disease in a subject, said method comprising administering to a subject in need thereof a therapeutically effective amount of an IL-2 variant comprising a sequence of amino acids that differs from SEQ ID NO: 1 only at one or more of residues E15, H16, Q22, D84, N88, or E95, wherein said IL-2 variant selectively promotes FOXP3-positive regulatory T cell growth or survival in vitro.

2. The method of claim 1 , wherein the IL-2 variant induces STAT5 phosphorylation in ex vivo FOXP3-positive T cells comprising a functional IL-2 receptor complex but has a reduced ability to induce phosphorylation of STAT5 in FOXP3-negative T cells.

3. The method of claim 1 , wherein the IL-2 variant is conjugated to a chemical or polypeptide that extends the serum half-life of said IL-2 variant in vivo.

Assignees

• Amgen Inc

Inventors

• Gavin Marc A
• Li Li

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title